Orelabrutinib with obinutuzumab and venetoclax for untreated MCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mantle cell lymphoma (MCL) and have never received treatment for it.
- You should be at least 18 years old and able to get around with little or no help (ECOG 0-2).
- You must have lymphoma that can be seen on scans or exams.
- Your blood counts (neutrophils and platelets) need to be high enough, unless your doctor thinks the low counts are due to the lymphoma.
- Your liver and kidney function must be adequate based on blood tests (e.g., creatinine clearance over 30 mL/min).
- You cannot have untreated or serious infections, other active cancers, heart disease, bleeding problems, or lymphoma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with Mantle Cell Lymphoma who have not yet received treatment. It aims to see if this combination works better than standard therapy, especially for those with high-risk features.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.